Targets › CYP11B1
8 programs from 8 companies in 11 trials: 5 Phase 4, 4 Phase 2, 2 Phase 1; Metabolic and endocrine, Neurology, Cardiovascular; next expected readout Dec 2026.
A cytochrome P450 monooxygenase mainly involved in the biosynthesis of adrenal corticoids. Catalyzes a variety of reactions that are essential for many species, including detoxification, defense, and the formation of endogenous chemicals like steroid hormones. (UniProt, P15538)
Open in Phaseline: the race on CYP11B1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| RECORDATI GROUP | Osilodrostat (LCI699) Cytochrome P450 11B1 inhibitor | CYP11B1 | Phase 4 | Hypertension; Cushing Syndrome; Mild Autonomous Cortisol Secretion (MACS) | Jul 2027 |
| Laikο General Hospital, Athens | Metyrapone Cytochrome P450 11B1, mitochondrial inhibitor | CYP11B1 | Phase 4 | Mild Autonomous Cortisol Secretion (MACS) | Nov 2027 |
| Washington State University | Metyrapone Cytochrome P450 11B1, mitochondrial inhibitor | CYP11B1 | Phase 4 | Shift Work Schedule | Mar 2029 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Metyrapone Cytochrome P450 11B1, mitochondrial inhibitor | CYP11B1 | Phase 4 | Adrenal Incidentalomas | – |
| West China Hospital | Mitotane Cytochrome P450 11A1 inhibitor; Cytochrome P450 11B1 inhibitor | CYP11A1, CYP11B1 | Phase 2 | Adrenal Cortical Carcinoma | Dec 2026 |
| H. Lundbeck | Lu AG13909 11β-hydroxylase inhibitor | CYP11B1 | Phase 2 | Cushing's Disease; Congenital Adrenal Hyperplasia | Aug 2027 |
| Actinogen Medical | Xanamem 11β-hydroxysteroid dehydrogenase type 1 inhibitor | CYP11B1 | Phase 2 | Dementia Moderate | Feb 2028 |
| University Medical Center Groningen | [18F]CETO tracer PET tracer with high specificity for steroidogenic enzymes CYP11B1 and CYP11B2 in adrenal | CYP11B1, CYP11B2 | Phase 1 | Primary Aldosteronism | May 2027 |
Mild Autonomous Cortisol Secretion (MACS) (2) Dementia Moderate (1) Hypertension (1) Cushing Syndrome (1) Adrenal Cortical Carcinoma (1) Cushing's Disease (1) Congenital Adrenal Hyperplasia (1) Primary Aldosteronism (1) Shift Work Schedule (1) Adrenal Incidentalomas (1)
small molecule (6), mixed (2)
Actinogen Medical (1) RECORDATI GROUP (1) West China Hospital (1) H. Lundbeck (1) University Medical Center Groningen (1) Laikο General Hospital, Athens (1) Washington State University (1) IRCCS Azienda Ospedaliero-Universitaria di Bologna (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.